Management of Chronic Bronchitis

Pharmacological Interventions

• Ipratropium bromide is recommended as first-line bronchodilator therapy for stable patients with chronic bronchitis (Grade A recommendation), and combined therapy with long-acting β-agonist and inhaled corticosteroid is recommended for stable patients (Grade A recommendation) 1, 2, 3, 4
• Short-acting β-agonists or anticholinergic bronchodilators should be administered during acute exacerbations of chronic bronchitis (Grade A recommendation) 2
• Central cough suppressants like codeine or dextromethorphan can be considered for short-term use for symptomatic relief of coughing (Grade B recommendation) 5
• Long-acting muscarinic antagonists (LAMAs) have a greater effect on exacerbation reduction compared to long-acting beta-agonists (LABAs), and are more effective for cough control than beta-agonists alone (Grade A recommendation) 6
• LABA/LAMA combinations provide superior efficacy for patients with inadequate response to LAMA monotherapy, increasing lung function and reducing symptoms compared to monotherapy, and reducing exacerbations more effectively than either monotherapy or ICS/LABA combinations (Grade A recommendation) 6
• Theophylline is not recommended for acute exacerbations (Grade D), and expectorants and mucokinetic agents are not recommended (Grade I) 1, 2, 3, 4
• Low-dose slow-release morphine (5-10 mg twice daily) may be effective for intractable chronic cough, but should be reserved for when alternative treatments have failed and cough significantly impacts quality of life, as suggested by the American College of Chest Physicians 7
• Gabapentin can be used as a first-line neuromodulator for persistent cough despite optimal treatment of common causes, after discussing potential side effects and risk-benefit profile (Grade B recommendation) 8, 7

1, 2, 3, 4

Non-Pharmacological Interventions

• Smoking cessation is the most effective intervention for chronic bronchitis, with 90% of patients experiencing resolution of cough after quitting, as suggested by the American College of Chest Physicians and the American Thoracic Society 2, 1
• Staying hydrated helps thin secretions, and avoiding irritants, such as smoke and pollutants, is recommended for patients with chronic bronchitis, as suggested by the American College of Chest Physicians and the American Thoracic Society 2, 6
• Annual influenza vaccination and pneumococcal vaccinations are recommended for all patients with chronic bronchitis, according to the Centers for Disease Control and Prevention 6
• Pulmonary rehabilitation should be considered to improve exercise tolerance and quality of life, as recommended by the American Thoracic Society 6
• Oxygen therapy should be considered for patients with low oxygen levels or evidence of pulmonary hypertension, peripheral edema, or polycythemia, according to the American Thoracic Society 6
• Environmental exposure avoidance, including reducing exposure to irritating inhalants and environmental pollutants, is recommended to manage chronic bronchitis, as suggested by the American Thoracic Society 1, 9
• Dietary and lifestyle modifications for GERD treatment include limiting fat intake to <45g/24h, avoiding certain foods and drinks, no smoking, and limiting vigorous exercise that increases intra-abdominal pressure, as suggested by the guidelines 10
• Acid suppression therapy for GERD should start with proton pump inhibitors (PPIs), and if no response is seen within 1-3 months, prokinetic therapy can be added, as recommended by the guidelines 10

Delivery of Therapy

• Oxygen should be used as the driving gas for nebulization whenever possible (Grade A recommendation) 11
• During acute exacerbations, combination therapy with ipratropium and beta-agonists may be beneficial (Grade A recommendation) 2
• A short course (10-15 days) of systemic corticosteroids is recommended (Grade A recommendation) for patients with chronic bronchitis, as suggested by the guidelines 2
• Antibiotics may be considered if purulent sputum is present, according to the American College of Chest Physicians, and should be reserved for patients with at least one key symptom (increased dyspnea, sputum production, or purulence) AND one risk factor (age ≥65, severe lung function impairment, ≥4 exacerbations/year, or comorbidities), as suggested by the Infectious Diseases Society of America 2, 1
• Regular assessment of symptoms, particularly cough and sputum production, should be performed, as recommended by the American Thoracic Society 6
• Monitor for development of worsening airflow obstruction and evaluate treatment adherence and inhaler technique at each visit, according to the American College of Chest Physicians 6
• Starting with LAMA as first-line therapy and evaluating response after 4-6 weeks is recommended, with the option to add LABA for LABA/LAMA combination if there is an inadequate response, as suggested by the guidelines 6